BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 9084061)

  • 1. Clocinnamox inhibits the intravenous self-administration of opioid agonists in rhesus monkeys: comparison with effects on opioid agonist-mediated antinociception.
    Zernig G; Lewis JW; Woods JH
    Psychopharmacology (Berl); 1997 Feb; 129(3):233-42. PubMed ID: 9084061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo determination of mu opioid receptor turnover in rhesus monkeys after irreversible blockade with clocinnamox.
    Zernig G; Butelman ER; Lewis JW; Walker EA; Woods JH
    J Pharmacol Exp Ther; 1994 Apr; 269(1):57-65. PubMed ID: 8169852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opioid thermal antinociception in rhesus monkeys: receptor mechanisms and temperature dependency.
    Walker EA; Butelman ER; DeCosta BR; Woods JH
    J Pharmacol Exp Ther; 1993 Oct; 267(1):280-6. PubMed ID: 7901396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clocinnamox distinguishes opioid agonists according to relative efficacy in normal and morphine-treated rats trained to discriminate morphine.
    Walker EA; Young AM
    J Pharmacol Exp Ther; 2002 Jul; 302(1):101-10. PubMed ID: 12065706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methoclocinnamox: time course of changes in alfentanil-reinforced responding in rhesus monkeys.
    Briscoe RJ; Winger G; Lewis JW; Woods JH
    Psychopharmacology (Berl); 2000 Mar; 148(4):393-9. PubMed ID: 10928312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antinociceptive and respiratory effects of nalbuphine in rhesus monkeys.
    Gerak LR; Butelman ER; Woods JH; France CP
    J Pharmacol Exp Ther; 1994 Nov; 271(2):993-9. PubMed ID: 7965822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo apparent pA2 analysis in rats treated with either clocinnamox or morphine.
    Walker EA; Richardson TM; Young AM
    Psychopharmacology (Berl); 1996 May; 125(2):113-9. PubMed ID: 8783384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clocinnamox antagonism of opioid suppression of schedule-controlled responding in rhesus monkeys.
    Butelman ER; Negus SS; Lewis JW; Woods JH
    Psychopharmacology (Berl); 1996 Feb; 123(4):320-4. PubMed ID: 8867870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methoclocinnamox: agonist and antagonist effects of a novel long-lasting opioid in rhesus monkeys.
    Butelman ER; Lewis JW; Woods JH
    J Pharmacol Exp Ther; 1996 Nov; 279(2):934-8. PubMed ID: 8930202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of mu-opioid agonists on cocaine- and food-maintained responding and cocaine discrimination in rhesus monkeys: role of mu-agonist efficacy.
    Negus SS; Mello NK
    J Pharmacol Exp Ther; 2002 Mar; 300(3):1111-21. PubMed ID: 11861822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. kappa-Opioid receptor effects of butorphanol in rhesus monkeys.
    Vivian JA; DeYoung MB; Sumpter TL; Traynor JR; Lewis JW; Woods JH
    J Pharmacol Exp Ther; 1999 Jul; 290(1):259-65. PubMed ID: 10381785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of gonadal steroid hormone treatments on opioid antinociception in ovariectomized rhesus monkeys.
    Negus SS; Mello NK
    Psychopharmacology (Berl); 2002 Jan; 159(3):275-83. PubMed ID: 11862360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of clocinnamox blockade of opioid receptors: evidence from in vitro and ex vivo binding and behavioral assays.
    Zernig G; Burke T; Lewis JW; Woods JH
    J Pharmacol Exp Ther; 1996 Oct; 279(1):23-31. PubMed ID: 8858971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Buprenorphine antagonism of mu opioids in the rhesus monkey tail-withdrawal procedure.
    Walker EA; Zernig G; Woods JH
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1345-52. PubMed ID: 7791107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of buprenorphine and other opioid agonists and antagonists on alfentanil- and cocaine-reinforced responding in rhesus monkeys.
    Winger G; Skjoldager P; Woods JH
    J Pharmacol Exp Ther; 1992 Apr; 261(1):311-7. PubMed ID: 1560376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiation of kappa opioid agonist-induced antinociception by naltrexone apparent pA2 analysis in rhesus monkeys.
    Ko MC; Butelman ER; Traynor JR; Woods JH
    J Pharmacol Exp Ther; 1998 May; 285(2):518-26. PubMed ID: 9580592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Self-Administration of cocaine-opioid combinations by rhesus monkeys: evaluation of the role of mu receptor efficacy using labor supply analysis.
    Rowlett JK; Rodefer JS; Spealman RD
    J Pharmacol Exp Ther; 2005 Mar; 312(3):1289-97. PubMed ID: 15550572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.
    Broadbear JH; Sumpter TL; Burke TF; Husbands SM; Lewis JW; Woods JH; Traynor JR
    J Pharmacol Exp Ther; 2000 Sep; 294(3):933-40. PubMed ID: 10945843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Receptor reserve and affinity of mu opioid agonists in mouse antinociception: correlation with receptor binding.
    Zernig G; Issaevitch T; Broadbear JH; Burke TF; Lewis JW; Brine GA; Woods JH
    Life Sci; 1995; 57(23):2113-25. PubMed ID: 7475964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Signal transduction efficacy of the highly potent mu opioid agonist 14-methoxymetopon.
    Zernig G; Saria A; Krassnig R; Schmidhammer H
    Life Sci; 2000 Mar; 66(19):1871-7. PubMed ID: 10809184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.